The additional biomarker study and clinical outcome of Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancer.

The additional biomarker study and clinical outcome of Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancer. - The additional study of a phase II study of Neoadjuvant Eribulin in TNBC patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018758

Enrollment

Registered

2015-08-24

Start date

2015-03-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. The patients who perticipate with Phase II study of Neoadjuvant Eribulin followed by FEC for operable triple-negative breast cancer. 2. A patient who gives written informed consent.

Exclusion criteria

Exclusion criteria: Patient considered irrelevant by attending physician for the study

Design outcomes

Primary

Measure	Time frame
Clinical outcome(Survival, relapse) Biomarkers	—

Countries

Japan

Contacts

Public ContactNoguchi Emi

National Cancer Center Hospital Breast and Medical Oncology

enoguchi@ncc.go.jp03-3542-2511

Outcome results